These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20177028)

  • 21. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
    Pacey S; Gore M; Chao D; Banerji U; Larkin J; Sarker S; Owen K; Asad Y; Raynaud F; Walton M; Judson I; Workman P; Eisen T
    Invest New Drugs; 2012 Feb; 30(1):341-9. PubMed ID: 20683637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.
    Hong D; Said R; Falchook G; Naing A; Moulder S; Tsimberidou AM; Galluppi G; Dakappagari N; Storgard C; Kurzrock R; Rosen LS
    Clin Cancer Res; 2013 Sep; 19(17):4824-31. PubMed ID: 23873691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
    Infante JR; Weiss GJ; Jones S; Tibes R; Bauer TM; Bendell JC; Hinson JM; Von Hoff DD; Burris HA; Orlemans EO; Ramanathan RK
    Eur J Cancer; 2014 Nov; 50(17):2897-904. PubMed ID: 25262379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
    Ramalingam SS; Egorin MJ; Ramanathan RK; Remick SC; Sikorski RP; Lagattuta TF; Chatta GS; Friedland DM; Stoller RG; Potter DM; Ivy SP; Belani CP
    Clin Cancer Res; 2008 Jun; 14(11):3456-61. PubMed ID: 18519777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
    Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S
    Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
    Isambert N; Delord JP; Soria JC; Hollebecque A; Gomez-Roca C; Purcea D; Rouits E; Belli R; Fumoleau P
    Ann Oncol; 2015 May; 26(5):1005-1011. PubMed ID: 25646368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
    Aregbe AO; Sherer EA; Egorin MJ; Scher HI; Solit DB; Ramanathan RK; Ramalingam S; Belani CP; Ivy PS; Bies RR
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):201-5. PubMed ID: 22450873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of hsp90 compromises the DNA damage response to radiation.
    Dote H; Burgan WE; Camphausen K; Tofilon PJ
    Cancer Res; 2006 Sep; 66(18):9211-20. PubMed ID: 16982765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.
    Palacios C; Martín-Pérez R; López-Pérez AI; Pandiella A; López-Rivas A
    Leuk Res; 2010 Nov; 34(11):1533-8. PubMed ID: 20667592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
    J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
    Goldman JW; Raju RN; Gordon GA; El-Hariry I; Teofilivici F; Vukovic VM; Bradley R; Karol MD; Chen Y; Guo W; Inoue T; Rosen LS
    BMC Cancer; 2013 Mar; 13():152. PubMed ID: 23530663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
    Oh WK; Galsky MD; Stadler WM; Srinivas S; Chu F; Bubley G; Goddard J; Dunbar J; Ross RW
    Urology; 2011 Sep; 78(3):626-30. PubMed ID: 21762967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
    Dote H; Cerna D; Burgan WE; Camphausen K; Tofilon PJ
    Cancer Res; 2005 Aug; 65(15):6967-75. PubMed ID: 16061682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
    Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
    Grem JL; Morrison G; Guo XD; Agnew E; Takimoto CH; Thomas R; Szabo E; Grochow L; Grollman F; Hamilton JM; Neckers L; Wilson RH
    J Clin Oncol; 2005 Mar; 23(9):1885-93. PubMed ID: 15774780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
    Doi T; Onozawa Y; Fuse N; Yoshino T; Yamazaki K; Watanabe J; Akimov M; Robson M; Boku N; Ohtsu A
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):629-36. PubMed ID: 25059319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
    Saitoh R; Nagayasu M; Shibahara N; Ono N; Suda A; Kato M; Ishigai M
    Drug Metab Pharmacokinet; 2014; 29(2):185-91. PubMed ID: 24126359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.
    Burris HA; Berman D; Murthy B; Jones S
    Cancer Chemother Pharmacol; 2011 May; 67(5):1045-54. PubMed ID: 20652703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.